Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Cancer deaths in people under 80 can be eliminated by 2050, says UCL report

Deaths from cancer in people under 80 years of age can be eliminated by 2050, a report from the UCL School of Pharmacy, ‘Overcoming cancer in the 21st century’, has predicted[1].

However, it warns that this is only possible if there is continued access to innovative treatments and improved prevention strategies. Since the early 1990s, age-standardised death rates from cancer have fallen by about 20% but the total burden of cancer has increased.

Speaking at a press briefing on 13 January 2015, the report’s author, David Taylor, emeritus professor of pharmaceutical and public health policy at UCL, said that the rhetoric surrounding cancer treatments is scaring people into believing they are unaffordable. He pointed out that Western nations only spend a tiny portion of GDP on cancer treatments; in the UK it is estimated to be 0.1%–0.2%. This, he said, is easily affordable if prioritised. “These drugs will revolutionise cancer treatment in the next 20 or 30 years,” he said, adding that there seems to be a culture of “blaming the innovators”.

Jack Cuzick, from the Wolfson Institute for preventive medicine at Queen Mary University London, advocated all adults aged 50–65 years should take a daily dose of aspirin to reduce their risk of bowel and other cancers. Research conducted by Cuzick and published in 2014[2] showed that if people did this for ten years, cases of cancer, hearts attacks and stroke would be reduced by 7% in women and 9% in men over 15 years and deaths would be reduced by 4% over 20 years.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067589

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.